title: Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
abstract: In 2015, 4 new drugs were approved for the treatment of patients with multiple myeloma who experience drug resistance and relapsing disease, offering potential for improved patient outcomes. Given the mortality, morbidity, and projected rise in the incidence of multiple myeloma, more effective, novel therapies and treatment combinations are needed for patients at each stage of the disease.
  
  
  
  Here, the authors examine published data regarding the development and clinical investigation of elotuzumab, a SLAMF7-targeted monoclonal antibody, for treatment of patients with multiple myeloma. The clinical efficacy, safety, and tolerability of elotuzumab treatment are summarized.
  
  
  
  Elotuzumab, a first-in-class immunostimulatory monoclonal antibody, is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received 1-3 prior therapies. Elotuzumab has the potential for use in patients in the upfront setting, in combination with other backbone regimens, as well as maintenance therapy. Trials demonstrate clinical benefit of adding elotuzumab to conventional lenalidomide and dexamethasone therapy, without additive toxicity. Data suggest that elotuzumab may provide clinical benefit in combination with proteasome inhibitors. Elotuzumab combination therapy is currently under further evaluation in the relapsed/refractory and newly diagnosed settings.
authors.affiliation: a Department of Hematology and Medical Oncology, Winship Cancer Institute , Emory University , Atlanta , GA , USA.
authors.forename: Sagar
authors.initials: S
authors.lastname: Lonial
authors.affiliation: a Department of Hematology and Medical Oncology, Winship Cancer Institute , Emory University , Atlanta , GA , USA.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Kaufman
authors.affiliation: b Department of Medical Oncology and Hematology , Princess Margaret Hospital , Toronto , Canada.
authors.forename: Donna
authors.initials: D
authors.lastname: Reece
authors.affiliation: c Haematology Department , Complejo Asistencial Universitario de Salamanca-IBSAL , Salamanca , Spain.
authors.forename: Maria-Victoria
authors.initials: MV
authors.lastname: Mateos
authors.affiliation: d Jerome Lipper Multiple Myeloma Center , Dana-Farber Cancer Institute , Boston , MA , USA.
authors.forename: Jacob
authors.initials: J
authors.lastname: Laubach
authors.affiliation: d Jerome Lipper Multiple Myeloma Center , Dana-Farber Cancer Institute , Boston , MA , USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Richardson
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003907:Dexamethasone / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D061988:Proteasome Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000071176:Signaling Lymphocytic Activation Molecule Family / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D061988:Proteasome Inhibitors; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family; C546027:elotuzumab; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide
keywords: CS1; IgG1; SLAMF7; elotuzumab; empliciti; monoclonal antibody; multiple myeloma